Solara Active Pharma Sciences
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Solara Active Pharma Sciences is currently positioned for a significant turnaround, as management emphasizes disciplined execution and operational efficiency to address profitability challenges, particularly in its Ibuprofen segment. The company's strategy focuses on geographic expansion and optimizing high-margin product lines, which aligns with Vista's forecast of accelerating revenue growth and improving margins. The partnership with Strides Pharma Science is expected to enhance operational resilience, providing stable order volumes that are crucial in the fragmented API market. Despite facing headwinds from supply chain volatility and high capital costs, Solara's commitment to maintaining a net debt-free position by FY29 and prioritizing high-ROCE investments supports Vista's positive outlook. The industry context, characterized by improving pricing power and a shift towards diversified supply chains, further bolsters Solara's growth potential. Over the next 12-24 months, key opportunities include successful resolution of the Ibuprofen business and effective execution of the CRAMS model, while watchpoints include potential supply chain disruptions and regulatory challenges that could impact operational efficiency
Why We Like This Stock
- Management's focus on operational efficiency and disciplined capital allocation is expected to enhance profitability
- The partnership with Strides Pharma Science provides stability and operational synergies critical for competitiveness
- The industry's improving pricing power and demand for diversified supply chains present significant growth opportunities
Things To Watch Out For
- Ongoing supply chain volatility and high capital costs pose risks to operational performance
- The need to resolve structural issues in the Ibuprofen segment could delay margin improvements
- Regulatory challenges may impact the execution of the product development pipeline
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,289 | 1,284 | 1,369 | 1,421 | 1,522 |
| Profit Before Tax (Cr.) | -298 | 1 | -1 | -17 | -14 |
| PBT Margin | -23.1% | 0.1% | -0.1% | -1.2% | -0.9% |
| Net Profit (Cr.) | -329 | 1 | -1 | -13 | -10 |
| Earnings Per Share | -68.6 | 0.2 | -0.2 | -2.6 | -2.2 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. It offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immuno-suppressant, loop diuretic, NSAIDs, anti-hyperkalaemia, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. The company also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical development, impurity synthesis, and regulatory support. In addition, it exports its products. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.